Why the study?
Does bevacizumab increase the risk of severe adverse events in patients with advanced cancer?
Population
Patients with advanced cancer (data pooled from 13 publications of randomized controlled trials)
Comparison
Bevacizumab vs Control group
Design
Meta-analysis
Authors
Loading...
Bevacizumab increases severe AE risk in advanced cancer; confirms and quantifies harm across trials to inform risk-benefit decisions.
Does bevacizumab increase the risk of severe adverse events in patients with advanced cancer?
In patients with advanced cancer, the addition of bevacizumab is associated with a 10% relative increase in the risk of severe (grade 3 or 4) adverse events, corresponding to a number needed to harm of 14.
Geiger-Gritsch et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: